BR9909357A - Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina - Google Patents

Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina

Info

Publication number
BR9909357A
BR9909357A BR9909357-0A BR9909357A BR9909357A BR 9909357 A BR9909357 A BR 9909357A BR 9909357 A BR9909357 A BR 9909357A BR 9909357 A BR9909357 A BR 9909357A
Authority
BR
Brazil
Prior art keywords
mirtazapine
water
solution
pharmaceutical formulation
suspension mixed
Prior art date
Application number
BR9909357-0A
Other languages
English (en)
Inventor
Arnold Titus Philip Skrabanja
Roger Edward Tully
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9909357A publication Critical patent/BR9909357A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)

Abstract

"SOLUçãO OU SUSPENSãO DE MIRTAZAPINA EM MISTURA COM áGUA, FORMULAçãO FARMACêUTICA COMPREENDENDO MIRTAZAPINA, E, USO DE MIRTAZAPINA" é verificado uma solução ou uma suspensão aquosa para a administração oral do antidepressivo mirtazapina que é de preferência estabilizada por metionina, é espessada e que tem um pH de 2,5 a 3 . Pela formulação de acordo com a invenção, é evitado um efeito anestésico local indesejável de mirtazapina.
BR9909357-0A 1998-04-02 1999-03-29 Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina BR9909357A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98201037 1998-04-02
PCT/EP1999/002277 WO1999051237A1 (en) 1998-04-02 1999-03-29 Oral liquid antidepressant solution

Publications (1)

Publication Number Publication Date
BR9909357A true BR9909357A (pt) 2000-12-12

Family

ID=8233550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909357-0A BR9909357A (pt) 1998-04-02 1999-03-29 Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina

Country Status (12)

Country Link
US (2) US6040301A (pt)
EP (1) EP1067934B1 (pt)
AT (1) ATE254918T1 (pt)
AU (1) AU747975B2 (pt)
BR (1) BR9909357A (pt)
CA (1) CA2326356C (pt)
DE (1) DE69913116T2 (pt)
DK (1) DK1067934T3 (pt)
ES (1) ES2212550T3 (pt)
HK (1) HK1032012A1 (pt)
PT (1) PT1067934E (pt)
WO (1) WO1999051237A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040156894A1 (en) * 2003-02-07 2004-08-12 Grother Leon Paul Use of edible acids in fast-dispersing pharmaceutical solid dosage forms
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
WO2006031720A2 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
JP2008519055A (ja) * 2004-11-08 2008-06-05 シャイア エルエルシー ミルタザピンと興奮剤複合物の併用投与の相乗効果
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
EP2567069A4 (en) 2010-05-05 2014-04-16 Ener G Rotors Inc FLUIDIC ENERGY TRANSMISSION DEVICE
US8714951B2 (en) * 2011-08-05 2014-05-06 Ener-G-Rotors, Inc. Fluid energy transfer device
DK3261645T3 (da) 2015-02-27 2021-06-07 Dechra Ltd Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
ATE99943T1 (de) * 1989-12-06 1994-01-15 Akzo Nv Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5238699A (en) * 1991-11-27 1993-08-24 Kraft General Foods, Inc. Ready-to-eat, low/no-fat puddings and process

Also Published As

Publication number Publication date
EP1067934A1 (en) 2001-01-17
CA2326356C (en) 2008-06-03
WO1999051237A1 (en) 1999-10-14
HK1032012A1 (en) 2001-07-06
DE69913116T2 (de) 2004-06-03
ATE254918T1 (de) 2003-12-15
DK1067934T3 (da) 2004-03-29
AU3604899A (en) 1999-10-25
CA2326356A1 (en) 1999-10-14
PT1067934E (pt) 2004-03-31
ES2212550T3 (es) 2004-07-16
US6040301A (en) 2000-03-21
US6114324A (en) 2000-09-05
DE69913116D1 (de) 2004-01-08
EP1067934B1 (en) 2003-11-26
AU747975B2 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
BR9909357A (pt) Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
BR0110841A (pt) Suspensões aquosas estabilizadas para uso parenteral
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
NO970051L (no) Vandige risperidon formuleringer
YU84703A (sh) Oralni rastvor aripiprazola
BR9917007A (pt) Moduladores de ccr5
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
BR0215042A (pt) fenil-naftalenos substituìdos como agentes estrogênicos
IS5198A (is) Ný efnasambönd
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
DE69818026D1 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DE69521122D1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
YU87501A (sh) Farmaceutski kompleksi
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
PT1283042E (pt) Preparação líquida aquosa de pranoprofeno
NO981340L (no) Stabiliserte fosfolipidsammensetninger
BR9907170A (pt) Composições farmacêuticas e métodos para uso

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/55, A61K 9/08, A61K 9/10, A61P 25/24

Ipc: A61K 31/55 (2007.10), A61K 9/08 (2007.10), A61K 9/

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGOS 8O E 13 DA LPI )

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.